After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull ...

Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye ...

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) came under pressure in the premarket on Tuesday after the company’s Q1 2025 ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported ...

The company’s $3 billion in earnings for the first quarter missed on both top and bottom line, according to BMO Capital ...

Currently, EYLEA HD is approved for dosing intervals of 8-16 weeks for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). For patients with diabetic ...

Truist lowered the firm’s price target on Regeneron (REGN) to $940 from $975 but keeps a Buy rating on the shares. The firm ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported first-quarter adjusted earnings per share of $8.22, down 14% ...

When a stock falls steadily on no news, that is a hint to avoid the company. Organon (OGN), a spin-off from Merck (MRK), continued to trade at a discount after posting results. The firm cut its ...

Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release ...

April 29 (Reuters) - Regeneron's (REGN.O), opens new tab first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking ...

(Reuters) -Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye disease drug Eylea, sending the company's shares tumbling 7% ...